-
Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma
Korst, C. L. B. M., O'Neill, C., Bruins, W. S. C., Cosovic, M., Twickler, I., Verkleij, C. P. M., le Clerre, D., Themeli, M., Chion-Sotinel, I., Zweegman, S., Galetto, R., Mutis, T. & van de Donk, N. W. C. J., 25 Jul 2024, In: Journal for Immunotherapy of Cancer. 12, 7, e008769.Research output: Contribution to journal › Article › Academic › peer-review
-
T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple Myeloma
Verkleij, C. P. M., O'Neill, C. A., Broekmans, M. E. C., Frerichs, K. A., Bruins, W. S. C., Duetz, C., Kruyswijk, S., Baglio, S. R., Skerget, S., de Oca, R. M., Zweegman, S., Verona, R. I., Mutis, T. & van de Donk, N. W. C. J., 15 Jul 2024, In: Clinical Cancer Research. 30, 14, p. 3006-3022 17 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step-up dosing
Korst, C. L. B. M., Groen, K., Bosman, P. W. C., van der Valk, F., Verkleij, C. P. M., Kruyswijk, S., de Ruijter, M. E. M., Heijink, D. M., Kuipers, M. T., Zweegman, S. & van de Donk, N. W. C. J., 1 Jul 2024, In: HemaSphere. 8, 7, e132.Research output: Contribution to journal › Letter › Academic › peer-review
- All publications
